Leucine-rich repeat and fibronectin type III domain-containing protein 1 mRNA 3' untranslated region (LRFN1 mRNA 3'UTR)

Leucine-rich repeat and fibronectin type III domain-containing protein 1 (LRFN1), also known as SALM2, is a transmembrane protein essential for the development and maintenance of excitatory synapses in the central nervous system (UniProt Q9HBL0). The 3' untranslated region (3'UTR) of the LRFN1 mRNA is a critical regulatory hub that controls the transcript's stability and translation efficiency through interactions with microRNAs, such as miR-124 and miR-137, and various RNA-binding proteins (NCBI Gene ID: 57473). Dysregulation of LRFN1 expression, often mediated by these 3'UTR interactions, has been implicated in the pathophysiology of neurodevelopmental and neuropsychiatric disorders, most notably schizophrenia and autism spectrum disorders (Wang et al., 2006). Furthermore, LRFN1 has been identified as a potential modulator in the progression of certain cancers, including gliomas, where its expression levels correlate with tumor cell proliferation and aggressiveness (Morimura et al., 2017). Targeting the LRFN1 mRNA 3'UTR represents an emerging therapeutic strategy, utilizing antisense oligonucleotides (ASOs) or microRNA-based therapies to precisely modulate LRFN1 protein levels. By influencing the post-transcriptional regulation of LRFN1, these interventions aim to restore synaptic balance or inhibit oncogenic processes. Currently, research into this specific target remains in the preclinical stage, with no approved drugs directly targeting this region.

Other names

SALM2 mRNA 3'UTRSynaptic adhesion-like molecule 2 mRNA 3'UTRLRFN1 3-prime untranslated region

Modulation of mRNA stability or translation through antisense oligonucleotides or microRNA-mediated gene silencing.